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Abstract
Endothelial cells (EC) participate in inflammatory and immune reactions by producing and responding to soluble
mediators. Human immunodeficiency virus (HIV)-1 profoundly alters the features of EC. In some anatomical
districts, they are infected by the virus and may represent a relevant reservoir. During lymphomononuclear cell
diapedesis, EC activate virus replication in crossing cells. Direct or indirect damage of EC is particularly relevant in
central nervous system, where blood-brain barrier perturbation is pivotal in neuronal degeneration. The observed
alterations of EC adhesive properties contribute in altered leukocyte traffic from blood to lymphoid organs and
tissues and play a role in the onset of immune surveillance alteration. These alterations of EC functions are relevant
for the general vasculopathy, which marks the acquired immunodeficiency syndrome, and in particular are instrumen-
tal in the pathogenesis of Kaposi’s sarcoma. Here we discuss the biological and molecular activation of EC in HIV-1
infection that represents the basis to understand the pathogenesis of HIV-1 associated vascular diseases. © 2001
Elsevier Science Ltd. All rights reserved.
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1. Introduction
Localized between blood and tissues, endothe-
lium represents a dynamic barrier that regulates
in–out and out– in signals resulting in the control
of body homeostasis. It contributes in blood rhe-
ology by its anti-thrombotic and pro-fibrinolytic
features, in delivering nutrients to and removing
wastes from tissues, and in traffic of blood cells.
Physical forces, alteration of soluble mediator net-
works or of the circulating concentration of
metabolites, enzymatic defects and host invasion
induce perturbations of endothelial cells (EC) and
cause changes of their genetic program. There-
fore, EC assume a pro-thrombotic and a pro-infl-
ammatory phenotype and actively participate in
the immune response by assuming properties of
antigen presenting cells and allowing leukocytes
to migrate in injured tissues or cancer cells to
metastasize. In adult life, activated EC may in-
crease their proliferative rate and generate new
vessels during tissue repair, growth of solid tu-
mors, chronic inflammatory and metabolic dis-
eases [1,2].
Human immunodeficiency virus (HIV)-1, the
etiologic agent of acquired immunodeficiency syn-
drome (AIDS), causes several vascular disorders
characterized by an evident activation and pertur-
bation of EC. These include vasculitis in several
organs [3–7] but in particular in central and
peripheral nervous system [8–10], serum protein
leakage across the blood-brain barrier [11],
thrombotic episodes [12–14], and enhanced
transendothelial migration of HIV-infected mono-
cytes in the brain that contributes to HIV-1-asso-
ciated encephalitis [15,16]. In addition, recent
evidence indicates the presence of severe morpho-
logic alterations of the aortic endothelium in
HIV-1-infected patients that are associated with
EC activation and increased adhesion of mononu-
clear cells [17]. Finally, infected patients show a
high susceptibility to manifest bacillary an-
giomatosis, an abnormal systemic vascular prolif-
eration with nodule formation characterized by
prominent angiogenesis and neutrophil infiltra-
tion, caused by the Gram-negative coccobacillus
Bartonella henselae [18,19].
However, the most profound mark of AIDS-as-
sociated vasculopathy is Kaposi’s sarcoma (KS).
KS is the most frequent tumor of HIV-1-infected
individuals, particularly homosexual men. Tu-
mors appear multifocally and are characterized by
endothelial cell activation and proliferation, as
well as by inflammatory infiltrate, particularly in
early stages. In progressed stages, the so-called
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KS spindle cells, which are regarded as the tumor
cells of KS, dominate the histological picture [20–
22].
The role of EC in the pathogenesis of AIDS is
not only restricted to the above mentioned patho-
logical settings. EC from specific anatomical dis-
tricts may be infected by HIV-1 and act as virus
reservoir [23–26] or facilitate infection spreading
in some tissues [27]. Finally, they regulate the
passage of infected lymphocytes to lymphoid or-
gans [28–30] and may contribute in metastasis
dissemination of AIDS-associated lymphomas
[31]. The involvement of EC in AIDS pathogene-
sis may be propelled by HIV-1 infection, by virus
products or by infective agents responsible of
opportunistic infections, that may alter EC
behavior.
This review will update the most important
aspects of EC interactions with HIV-1 and will
emphasize the role of the activation of these cells
in the pathogenesis of AIDS associated diseases,
in particular of KS.
2. Restricted susceptibility of EC to HIV-1
infection
Cellular entry of HIV-1 requires binding to
both CD4 and to one of the seven transmembrane
G-protein-coupled chemokine receptors, which
act as co-receptors. HIV-1 strains have earlier
been characterized by their ability to produce
syncytia following infection of neoplastic cell lines
(viral phenotype). Syncytium inducing viruses are
frequently found in progressive or late-stage HIV
disease while nonsyncytium-inducing viruses are
present throughout disease. HIV-1 can also be
classified by its ability to infect primary
macrophages and CD4+ T cell lines (cell
tropism). All HIV-1 isolates can replicate in pri-
mary T cells. However, syncytium-inducing iso-
lates that have adapted to T cell lines cannot
replicate in macrophages, whereas some, but not
all, primary non-syncytium inducing and syn-
cytium inducing isolates can infect macrophages.
This simple paradigm is complicated by the pres-
ence of dual tropic HIV-1 strains containing both
syncytium inducing and non-syncytium inducing
constituents capable of infecting both T cell lines
and primary macrophages. With the discovery of
the chemokine receptor family as HIV-1 entry
co-receptors, HIV-1 strains can also be classified
by co-receptor utilization. Strictly non-syncytium
inducing (T cell tropism) viruses primarily utilize
CC receptor (R) 5, whereas strictly syncytium-in-
ducing viruses (macrophage tropism) primarily
utilize the chemokine receptor CXCR4. However,
most primary syncytium inducing isolates use
CXCR4 in conjunction with CCR5. Not all non
syncytium-inducing isolates are capable of infect-
ing macrophages and not all CCR5-using isolates
can infect macrophages. Furthermore, some HIV-
1 strains can infect the cells through a CD4-inde-
pendent way [32,33].
EC may be infected by lentiviruses but there are
differences related to EC heterogeneity. EC from
large vessel do not express CD4 molecule but may
be infected by different strains of HIV-1 and
HIV-2 [26,34,35] through CXCR4 [36] that is
constitutively expressed on this cell type [37]. The
stromal-derived factor-1, the ligand of CXCR4,
may down-modulates its receptor and reduces the
virus entry [38]. In this type of EC mature virus
production is evident during the first days after
infection but then declines to undetectable levels,
both in the supernatants and in the cell. However,
in co-culture experiments with infected EC from
large vessels and CD4 positive lymphoid cells or
mononuclear cells, it has been demonstrated a
productive HIV-1 infection with syncytia forma-
tion of lymphoid cells [35]. This rescue activity of
T cells and monocytes is enhanced by interferon
(IFN)- and by RANTES through the up-regula-
tion of intercellular adhesion molecule-1 (ICAM-
1) on EC surface. This adhesion molecule seems
to be pivotal in rescue mechanism, as inferred by
the inhibitory role of antibodies anti-ICAM-1 in
the establishment of a productive infection in the
co-culture [39,40]. It is possible that ICAM-1
triggered by LFA-1 expressed on adhering
lymphomononuclear cells elicits positive signals
for virus replication. Similarly, the treatment of
EC from large vessels with inflammatory cytokine
[(i.e. tumor necrosis factor- (TNF-) or inter-
leukin (IL)-1] allows virus replication [41]. These
data suggest that EC from large vessels are a
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reservoir of HIV-1 that is activated when EC are
perturbed.
Microvascular EC from brain, kidney
glomeruli, hepatic sinusoid and bone marrow may
be infected by HIV-1 and let virus replication
without cytolysis [23–26,41]).
The infection of brain EC have been extensively
studied for its relevance in neurological diseases
associated to HIV-1 infection and for therapeutic
implications because the central nervous system
also may act as a persistent reservoir of virus since
antiviral agents penetrate the blood-brain barrier
poorly. T-cell tropic but not brain-derived
macrophage tropic HIV strains selectively infect
in vitro brain endothelium suggesting that T-cell
tropism is important for HIV entry through the
blood-brain barrier [23,27] and for in vivo infec-
tion of EC in central nervous system [42–44]. A
detailed analysis performed by Moses and co-
workers excluded a role for CD4 and galactosyl-
cerebroside in EC infection and may suggest the
existence of strains with a specific tropism for
brain EC besides those with a double specificity
for EC and macrophages or CD positive cells
[23,24]. The viral sequences responsible for EC
infection map to a region that encompasses the
C1 region of en and includes overlapping reading
frame for the accessory genes pr, pu, tat, and
re.
A role for the gp120 glycoprotein viral coat has
also been suggested as mediator the adsorptive
endocytosis of the virus in brain EC [45] by
interaction with a CCR5 or CXCR4 [46]. How-
ever, it has not been exactly established the recep-
tor used by HIV-1 to infect cerebral EC. EC have
CXCR4 receptor [37] and express CCR5 at site of
inflammatory injury [47] and both may sustain
CD4-independent cell infection [32,48–50]. Rhe-
sus brain EC are preferentially infected by
macrophage-tropic simian immunodeficiency virus
(SIV) [51,52], which uses as primary receptor
CCR5 [49]. It is intriguing that circulating
mononuclear cells transfer CCR5 to EC during
transendothelial migration and enhance the sus-
ceptibility of EC to a productive infection during
chronic inflammation [53]. Additional orphan
chemokine receptors that can mediate HIV-1 or
SIV cell entry could be also involved in EC
infection.
The susceptibility of brain EC to a productive
HIV infection may be relevant for neurological
problems associated to AIDS. Through infected
EC, HIV-1 may easily spread to the brain and
manifests its neuropathogenicity. Alternatively the
productive infection may alter features of blood-
brain barrier and thus favor the infiltration of
infected cells or of HIV-1 itself [54].
3. Direct effect of HIV-1 on EC behavior
On the light of low and discrete susceptibility of
EC to be infected by lentiviruses, there are few
data on the their direct effects. Infected EC show
a selective impairment in the storage and/or excre-
tion of molecules such as endothelin-1 and Von
Willebrand factor [55]. The in vitro cytotoxicity is
negligible, but EC apoptosis occurs in small and
medium-sized blood vessels in the brain of AIDS
patients [56], an abnormality that might disrupt
the blood-brain barrier [11]. It is likely that EC
apoptosis may be induced by soluble stimuli re-
leased by immunocompetent and stromal cells or
by viral proteins. Among them, HIV-1 gp120 is
able to activate an apoptotic program in EC
isolated from large vessels [46] and changes the
function barrier of microvascular EC monolayer
by increasing vasopermeability to middle-sized
proteins [57].
4. Indirect effect of HIV-1 on EC behavior: the
role of Tat
Tat is a transcriptional activator of viral gene
expression produced early after infection and es-
sential, for virus replication. The protein is com-
posed of 86–104 aminoacids (according to viral
isolate) encoded by two exons. In the portion
encoded by the first exon (72 amino acids), four
distinct regions can be recognized (N-terminal,
cysteine rich, core and basic). The second exon
encodes the C-terminal region containing a RGD
sequence [58]. During acute infection of T cells by
HIV-1, Tat is released from the cells in an active
form [59,60] and via a leaderless secretory path-
way that is specific and resembles that of IL-1 and
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fibroblast growth factors (FGF) [60]. In addition
to its effect on paracrine and autocrine virus
replication, it possesses other activities on cell
functions. Tat easily enters different cell types
contributing to the transactivation of HIV-1 long
terminal repeat promoter in latently infected cells
[61,62]. Alternatively, it acts as soluble mediator
affecting physiologic functions of cells including T
and B cells, monocytes, chondrocytes and neurons
[63–68]. However, one of the most relevant
targets for Tat is the vascular system, where it
activates a pro-inflammatory and angiogenic pro-
gram. Tat can up-regulate the expression of EC
adhesion molecules [69,70] and induces EC to
proliferate, release proteolytic enzymes [71–79].
These effects are potentiated by cell priming with
inflammatory cytokines [71,72,80]. Finally, Tat
induces EC adhesion to proteins of extracellular
matrix and stimulates EC to undergo in vitro
morphogenesis [73,78]. The counter part of these
in vitro effects of Tat on EC is its in vivo angio-
genic activity [73–76,81].
The molecular mechanisms leading to EC acti-
vation by Tat had been extensively studied. Infl-
ammatory cytokines, and in particular IFN-,
render EC in vitro more responsiveness to Tat by
inducing the expression of 51 and v3 inte-
grins [72,78,82] that is a feature of activated,
angiogenic EC in vivo [83]. Through its RGD
sequence, Tat binds integrins [84,85] that signal
inside the cells [86], and induces the phosphoryla-
tion of p125 focal adhesion kinase (B. Ensoli,
unpublished data). Furthermore, inflammatory
cytokines induce basic FGF expression that, in
turn, induces the same integrins [80,82] and it is
required for Tat-angiogenic effect [74]. The basic
domain of Tat may compete with basic FGF for
binding to heparin sulfate proteoglycans of the
cell surface and extracellular matrix [87] and ren-
der the growth factor able to activate EC [79].
Additionally, Tat binds to and activates the
tyrosine kinase receptor encoded by KDR [vascu-
lar endothelial growth factor (VEGF) receptor
(R) 2] in EC and Kaposi’s cells [76,81,88–91]. The
natural ligands of VEGFR2 belong to the VEGF
family [92] and a neutralizing antibody anti-
VEGFR2 or cross-desensitization between Tat
and VEGF-A165 block the activation of the recep-
tor as well as the migration of EC triggered by
Tat. These results are also supported by recent
data showing that Tat has vasopermeabilizing
effect by a direct action on EC [93,94], as demon-
strated earlier for VEGF-A [92]. These effects are
blocked by functional inactivation of VEGFR-2
[93].
To identify functionally important domains re-
sponsible for the activation of the angiogenic
program in vascular EC, a structure-activity rela-
tionship study of Tat protein has been performed
[81]. Tat binds EC with high (Kd10–30 pM)
and low affinity (Kd1–2 nM). The basic and
the cysteine-rich domain mediate the former. Tat
basic domain is crucial for the binding and the
activation of VEGFR-2. The relevance of the
positively charged aminoacids in performing these
functions is consistent with the observation that
the charged residues R82, K84, H86 of VEGF-A
are important for VEGFR-2 recognition [95].
Since it has been suggested that Tat forms a dimer
bridging cysteine-rich regions from each monomer
[61] and that two cysteine residues are pivotal for
the VEGF-A dimerization and the subsequent
binding to and activation of endothelium [96], it
could be hypothesized that the active form of Tat
on endothelium has a dimeric structure. The rele-
vance of this domain has been also emphasized by
Albini and co-workers who demonstrated its role
in the migration of monocytes [97] another Tat
function that requires VEGFR1 [64,98]. The C-
terminus region of Tat containing RGD sequence
is involved in the low affinity binding sites. Mu-
tants in this sequence or Tat72 that lacks the
product of exon 2, have reduced biological activ-
ity in vitro and in vivo, which is consistent with
the earlier reports showing that integrins v3
and v5 participate in Tat-induced activation of
EC [72,78,79]. All together, these data suggest
that regions encoded by the first exon of tat are
necessary and sufficient for activation of VEGFR-
2. However, the C-terminal region, through
RGD-mediated integrin engagement, is indispens-
able for a full activation of an in vitro and in vivo
angiogenic program. These results are not contra-
dictory and it is possible that Tat stimulates EC
by an independent activation of integrin system
and VEGFR-2 that achieve a synergy in term of
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biological functions. However, integrins and in
particular v3, show a regulatory activity on
tyrosine kinase receptors [89,99,100]. We have
recently shown that integrin v3 is associated to
VEGF-A-stimulated VEGFR-2 and that a mono-
clonal antibody against 3 integrin inhibits the
activation of the receptor [89]. The blocking ef-
fects of neutralizing antibody anti-v3 or anti-
VEGFR-2 [75,76,79,89] and the mapping studies
performed with mutants [81] or with overlapping
Tat peptides [75,76,79] suggest that Tat is a
unique example of molecule which turns on intra-
cellular signals by a direct activation of both
receptor and integrin systems. Furthermore, be-
side to have a direct role in integrin activation, the
C-terminus region of Tat could regulate VEGFR-
2 through the presence of other determinants
relevant for the engagement of neuropilin-1, a
co-receptor of this tyrosine kinase receptor
[101,102].
5. Regulation of leukocytes diapedesis by EC
The changes in soluble mediator networks char-
acterize the early and late events of HIV-1 infec-
tion [103,104] and the abnormal increased of
circulating inflammatory cytokines [TNF-, IL-1,
IL-8, monocyte chemotactic peptide (MCP) -1]
renders EC more adhesive and favors the dia-
pedesis of circulating cells [17]. Furthermore, the
presence of HIV in lymphomononuclear cells, the
viral proteins Tat, Nef and gp120 and the unbal-
ance of cytokine system alter the expression of
adhesion molecules (CD11a/CD18, CD49d/CD29,
CD58, CD62L, CD44) on cell membrane and
modify the transmigration properties of circulat-
ing cells across the vessel walls [28,70,106–111].
Furthermore, Tat also may modify the adhe-
sion molecule profile in EC. As mentioned before,
Tat induces the expression of E-selectin, up-regu-
lates ICAM-1 and VCAM-1 in macrovascular
and microvascular EC [69,70,112,113] and sup-
ports leukocyte adhesion. Furthermore, it stimu-
lates transcription and release of IL-8 [112] and
MCP-1 [93] that are powerful leukocytes
chemoattractants. In vivo, the effect of Tat on
leukocyte recruitment is preceded by an increased
in vascular permeability, which is caused by the
synthesis of platelet-activating factor in EC and
may facilitate cell transmigration [93].
The role of EC in the control of leukocyte
diapedesis is crucial in the development of AIDS.
During transmigration, the engagement of the
integrin system on infected lymphomononuclear
cells and the production of inflammatory cytoki-
nes by EC result in viral replication in
lymphocytes and monocytes [114,115], thus influ-
encing the passage of HIV-1 from latency to
productive replication and enhancing virus
spreading. Furthermore, abnormal leukocyte
traffic in is instrumental to progressive injury of
lymphoid tissue and impairment of immune re-
sponse. Similarly, leukocyte infiltration and ab-
normal cytokine response are typical features of
HIV-1-associated tissue pathologies, including tu-
mors, opportunistic infections and central nervous
system degeneration [103–105,116].
6. Kaposi’s sarcoma
KS is a multifocal proliferative disease of vas-
cular origin found in four clinic-epidemiological
forms. AIDS-associated KS (AIDS-KS) is the
most frequent tumor of HIV-l infected homo-bi-
sexual men and is the most aggressive form of KS
[21]; African KS (AKS) is frequent in certain
areas of Africa, where it can represent up to 10%
of the total tumors and acquires a very aggressive
course after HIV-1 infection [117]; classical KS
(CKS) occurs in elderly men of the Eastern–Med-
iterranean area and is a milder form of the disease
[118]; post-transplant KS (PKS) occurs in trans-
planted individual after therapy with cyclosporin
and corticosteroids [119]. Although these forms
have a different geographical distribution and
clinical course they share many common features
including (i) a disturbance of the immune system
characterized initially by immunoactivation par-
ticularly of CD8 T cells with Th1-type cytokine
production and later, at least for AIDS-KS and
PKS, by immunosuppression; (ii) histopathology
of the lesions; (iii) high levels of the same inflam-
matory cytokines, angiogenic molecules and
growth factors in the lesions; and (iv) infection by
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human herpesvirus-8 (HHV-8). These and other
features of KS lesions and KS patients suggest
that the different epidemiological forms of KS are
mediated by the cooperation of the same cytoki-
nes and viral agents.
In vitro and in vivo experimental data and
clinical observations indicate that KS may not be
a true sarcoma at least in early stages but it can
develop as a reactive process mediated by inflam-
matory cytokines and angiogenic factors whose
production is triggered or enhanced by infection
with HHV-8. In this context, the Tat protein of
HIV-1 can increase the frequency of development
and the aggressiveness of AIDS-KS. The role of
cytokines, the lack of malignancy of isolated cell
cultures, the lack of chromosomal alterations, the
onset of KS as simultaneous multiple lesions in
the absence of obvious metastasis and lastly, the
sporadic cases of tumor regression support the
hypothesis of the reactive nature of KS [120].
However, recent evidence also suggests that in
later stages of development, reactive KS lesions
may transform to a true sarcoma [121,122].
KS lesions are characterized by multiple patch,
plaque or nodular lesions particularly on the skin
of the extremities but often involving also the
mucosae and visceral organs, particularly in
AIDS-KS. The nodular stage represents a late
‘tumoral’ stage of the lesions and is often found at
onset in AIDS-KS patients from Africa [22,123].
Histologically, early lesions are characterized
by an inflammatory-granulation type reaction
with activated proliferating EC, which form new
blood vessels often abnormal that allow extrava-
sation of red blood cells and edema. This can
precede the appearance of the typical ‘spindle
cells’ (KS cells) that are considered to be the
tumor cells of KS. On time, the spindle cells
become the predominant cell type and the lesions
acquire a more monomorphic aspect resembling a
fibrosarcoma, although angiogenesis remains al-
ways a prominent feature [124,125].
The nature of the inflammatory cell infiltrate of
KS appears of importance since it is the first to
appear and precedes the spindle cell formation.
Immunohistochemical studies indicate a prevalent
infiltration of T cells dominated by CD8+ cells
but also containing CD4+ cells, numerous mono-
cyte-macrophages (CD4+, CD14+, CD68+,
CD45+, PAM-1+) often with a spindle-like mor-
phology and a subendothelial localization, den-
dritic cells (FX111a1) and few B cells (CD19+,
CD20+ or CD30+) [126–129]. In addition, the
enhanced expression of adhesion molecules in res-
ident vessels and the lack of evidence of mono-
cytic cell proliferation in KS indicate that
monocytes are recruited from the blood and dif-
ferentiate in loco in macrophages and dendritic
cells [130]. Therefore, KS cells produce chemoki-
nes which are able to recruit inflammatory cells
[131–134]. As discussed later, these inflammatory
cells, mostly CD8+ cells and monocytes-
macrophages, produce a variety of cytokines and
in particular IFN-, that function in a synergistic
fashion to activate EC, to induce the production
of angiogenic factors and a further recruitment of
T cells and monocytes.
The nature of KS ‘spindle’ cells has been de-
bated for a long time. Recent studies indicate that
these cells are a heterogeneous population with
three distinct phenotypes, one reminiscent of acti-
vated vascular and lymphatic EC, the other one
of macrophagic and dendritic cells, the last of
characterized by the presence of mixed markers of
macrophage and EC [126–128,135,144].
The reactive or hyperplastic KS cells are not
transformed nor they induce tumors in nude or
SCID mice, however, they promote highly angio-
genic lesions of mouse cell origin that closely
resemble early human KS lesions [121,122,136–
138]. These lesions regress as early KS lesions can
regress in humans and, as discussed below, are
mediated by the angiogenic cytokines and growth
factors produced by KS cells. However, although
most spindle cells and, perhaps all in early stage,
are reactive cells, recent evidence suggests that KS
cells are ‘trans-differentiated’ cells and that in late
stage, they may transform [121,122,139].
Two transformed cell lines have been estab-
lished from KS lesions that are able to give tu-
mors in SCID but not in nude mice [121,122,140]
suggesting that tumorigenic growth may require a
serious host immunodeficiency. In addition, recent
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studies on nodular AIDS-KS lesions from African
women indicate monoclonality of spindle cells
[141]. However, due to the mixed cellularity, this
type of studies cannot be performed on early
lesions. On the other hand, others have also found
polyclonality of the lesions [142] suggesting that
tumor transformation may occur in some cases of
advanced KS patients that are severely immuno-
compromised such as African AIDS-KS patients.
Consistent with this, microsatellite instability has
been observed in AIDS-KS but not in the absence
of HIV-1 infection such as in CKS lesions [143].
7. The role of CD8+ cells and inflammatory
cytokines in Kaposi’s sarcoma
Clinical observations suggest a role for a CD8+
cell activation and production of inflammatory
cytokines of the Th-1 type (IFN- and IL-2) in
KS development [22]. Recent evidence indicates
that this is the case. In fact, activated peripheral
blood mononuclear cells from both AIDS-KS and
CKS patients produce high levels of IFN- and
little or no IL-4 as compared with patients with-
out KS but with other dermatological disorders
[144]. CD8+ cell and macrophage activation with
cytokine production is also found in KS lesions
from the same patients [126,144]. Thus, im-
munoactivation is a trait of individuals developing
KS and production of cytokine including IFN-,
IL-1, TNF- appears to be key to KS develop-
ment. In fact, the administration of IFN-, IL-2
or TNF- to KS patients leads to disease progres-
sion or to KS development [145,146].
A variety of inflammatory cytokines is ex-
pressed in lesions from all forms of KS. These
include IFN- , TNF-, IL-1, IL-6, granulocyte/
macrophages colony stimulating factor, onco-
statin-M [126,144,147–149]. They are all
produced by infiltrating leukocytes. This cytokine
production is associated with vessel activation
(ICAM-I+, ELAM-I+, VCAM-1+, DR+,
CD40+, up-regulation of 51 and v3 inte-
grins) [74,126,127] and increased vascular adhe-
sion of inflammatory cells [17].
Cytokines produced by activated T cells induce
the long-term growth of cultivated KS cells,
[150,151] and increase the in vivo angiogenic po-
tential of KS cells [80]. Among them, oncostatin-
M and IL-6, in particular, have been found to be
strong KS cell growth factor [149,207,208]. How-
ever, it is clear that the effect of cytokines on KS
cell growth is mediated by a synergistic stimula-
tory effect on production of angiogenic inducers.
Besides basic FGF [74], inflammatory cytokines
produced in KS lesions also induce cultured EC
and KS cells to produce angiogenic molecules,
and other cytokines and chemokines with effects
on cell recruitment, growth, angiogenesis and le-
sion formation (discussed below). In addition,
upon exposure to inflammatory cytokine EC be-
come angiogenic in nude mice and induce forma-
tion of KS-like lesions as KS cells do [71,80].
Similarly, inoculation of inflammatory cytokines
induces KS-like angiogenic lesions in mice [79],
indicating that they can trigger a cascade of
events leading to lesion formation.
IFN- appears to be the major mediator re-
sponsible for this cascade, although IL-1 and
TNF- contribute in these effects in a synergistic
fashion [71,80]. In addition, IFN- up-regulates
CD40 expression in cultured KS cells [152] and
supports the progression of the lesion by its anti-
apoptotic and pro-angiogenic effects probably by
induction of the expression of the bcl-2 proto-
oncogene [153,154].
Altogether, these results indicate that the cy-
tokines produced in KS lesions are capable of
triggering a cascade of events leading to lesion
formation and to maintenance and progression of
KS.
8. The role of angiogenic inducers in Kaposi’s
sarcoma
The first experimental evidence that angiogenic
factors are involved in KS lesion formation was
provided by studies indicating the capability of
KS cells to induce angiogenesis in the chorioallan-
toic membrane assay and highly angiogenic KS-
like lesions after inoculation of the cells in nude
mice [138,151,74]. These KS-like lesions are of
mouse cell origin suggesting that these cells are
able to recruit normal vascular cells, a phe-
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nomenon also observed in mice injected with hu-
man cells carrying mT oncogene of polyoma virus
[156]. Lesions regress in time and are mediated by
specific angiogenic factors produced by the cells.
In particular, basic FGF is a key mediator of
lesion formation. Inoculation of basic FGF in
nude mice results in the formation of KS-like
lesions [74]. In addition to its paracrine activity,
basic FGF has autocrine activity in KS develop-
ment because it stimulates proliferation KS cells
[80,157]. Most importantly, both basic FGF
mRNA [158] and protein [74] are highly increased
in tissue sections of KS primary lesions and in KS
cells. This indicates that basic FGF regulates an-
giogenesis and KS growth in humans and in urine
models.
However, neutralizing anti-basic FGF antibod-
ies or antisense oligodeoxynucleotides do not to-
tally block lesion formation after inoculation of
KS cells in mice [155] and injection of basic FGF
alone does not induce the edema characteristic of
KS [74]. This suggests involvement of other fac-
tors. In fact, VEGF-A, is expressed as the two
secreted forms (VEGF-A121, VEGF-A165) in both
KS lesions and in cultured KS cells [157,159,160]
and its plasmatic levels are increased in patients
affected by KS [161,162]. VEGF-A synergizes
with basic FGF in inducing endothelial cell
growth and angiogenesis as demonstrated by in
vitro and mice studies [157,159]. VEGF-A induces
the proliferation and the migration of KS cells
[160,163] though activation of VEGFR2 and in-
volvement of c-src and a specific adhesion focal
tyrosine kinase [164,165]. The herpes virus HHV-
8, a transmissible agent bas been postulated as the
causal agent of KS (see below) and it has been
recently shown that it increases the transcription
of VEGF-A and VEGFR-2 [166,167]. Two other
members of VEGF family, VEGF-C, which is
expressed in KS lesion [168], and VEGF-D are
able to activate the migration of KS by activating
VEGFR1 and VEGFR2 [136,169].
Angiopoietins, which act through another ty-
rosine kinase receptor, Tie-2, are expressed in KS
lesions [170] and may be important in the matura-
tion of nascent vessel. In fact, these molecule do
not show any proliferative activity but induce cells
carrying the specific receptor to release molecules
that recruit pericytes and smooth muscle cells
around nascent vessels [171].
Another angiogenic molecule found in KS is
hepatocyte growth factor (HGF) [90,172]. HGF
induces EC to acquire spindle morphology and
stimulates proliferation of cultured KS spindle
cells. Moreover, HGF and its cognate receptor,
the c-met protein, are expressed in human KS
lesions, suggesting that it may play a role in KS
development.
Platelet derived growth factor-B (PDGF) is an-
other potent paracrine-acting mitogen for cul-
tured KS cells that is expressed in vivo by
subpopulations of cells that are intermingled with
the spindle cells [173]. KS cells express PDGF
-receptor, suggesting that PDGF-B may activate
the proliferation of KS cells by paracrine mecha-
nisms. In addition, PDGF-B may have angiogenic
activity suggesting that it may also contribute in
the angiogenesis found in KS [173–177].
Platelet-activating factor is an autacoid
molecule, which activates the migration of KS in
autocrine manner [178,179] and has angiogenic
activity [180].
Altogether these data indicate that a network of
angiogenic factors and spindle cell growth factors
are expressed in KS and regulate recruitment,
survival, growth and differentiation of the differ-
ent cell types, including spindle cells, present in
KS lesions. The biological activities of these
molecules and of the cytokines discussed above
can explain the mixed cellularity and the angio-
genesis of KS lesions in the context of a cytokine-
mediated reactive process.
9. The role of human herpes virus 8 and of
HIV-1 Tat in Kaposi’s sarcoma
Although a transmissible agent bas been postu-
lated as the causal agent of KS and several viruses
and other agents have been suggested [22], none
has been confirmed. Recently a new herpesvirus
termed human Herpesvirus 8 (HHV-8), that is
closely related to Epstein-Barr-virus and her-
pesvirus saimiri, has been identified and shown to
be present in all epidemiological forms of KS
[181–183]. Since HHV-8 seroprevalence is low in
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areas at low incidence of KS and its detection
can precede the onset of KS [184–186], these
results suggest that HHV-8 is key to KS devel-
opment but it requires additional factors to ex-
ert its effects in KS pathogenesis.
At the lesion level, HHV-8 is present in en-
dothelial and spindle cells mostly in a latent
form, [187,188] whereas mononuclear cells in-
cluding monocytes-macrophages are lytically in-
fected [189] and may support virus production
and spread to other cell types.
The question whether extravasation of HHV-8
infected mononuclear cells into the tissue may
be the initiating event of KS development or
whether these cells are recruited secondarily into
an early reactive focus of KS has not yet been
solved. The second hypothesis, however, is sup-
ported by recent data showing that in late stage
KS lesions numerous KS spindle cells express
the latency associated nuclear antigen and the
kaposin gene (expressed in lytic and latent infec-
tion) of HHV-8, whereas in early KS lesions
this antigen expression is not detected, and the
relative number of cells (i.e. the number of posi-
tive cells/total number of KS cells) expressing
kaposin is much lower as compared with late
stage lesions [187,188].
As other herpesviruses, HHV-8 possesses sev-
eral homologs of cellular genes including cytoki-
nes (v-IL-6), chemokine receptors (v-IL-8R),
chemokines (V-MIP I, II and III), viral FLICE-
inhibitory protein (vFLIP) and potentially trans-
forming genes like v-bcl-2 and v-cyclin D
[190–193]. However, most of these genes are ex-
pressed during lytic infection and not in latently
infected KS spindle cells and only v-cyclin D
and vFLIP expression can be detected by in situ
hybridization in numerous KS spindle cells of
late, but not early nodular KS lesions [194]. It is
intriguing to remember that vFLIP induces a
protection of virus-infected cells against death-
receptor-induced apoptosis and may lead to
higher virus production and contributes to the
persistence and oncogenicity of HHV-8 [195].
So, HHV-8 may be an accessory activator of
KS spindle cell growth possibly mediated by v-
cyclin D [186] or may act indirectly by stimulat-
ing the expression of cellular factors with
paracrine activity.
In addition to these genes, HHV-8 encodes
three chemokine ligands with interesting func-
tional characteristics and two of them, vMIP-I
and -II, can promote angiogenesis [196]. Trans-
genic mice expressing the HHV8-encoded viral
G protein–coupled receptor (GPCR, a homo-
logue of CXCR1and CXCR2) within hemato-
poietic cells develop angioproliferative lesions in
multiple organs that morphologically resemble
KS lesions. These lesions are characterized by a
spectrum of changes ranging from erythematous
maculae to vascular tumors, by the presence of
spindle and inflammatory cells, and by expres-
sion of VEGF-A [197]. This viral protein is a
constitutively signalling receptor that can bind
chemokines from the CXC and the CC families,
but does not require ligand for its activation
[198]. It was shown that signalling by HHV-8
leads to the up-regulation of expression of
VEGF-A, thereby inducing angiogenesis via a
paracrine mechanism(s). In KS lesions, there is a
small subset of cells expressing lytic genes that
appear to be productively infected with HHV-8
[199] and GPCR is expressed by these scattered
cells. Therefore, it can be argued that in KS
lesions the expression of this viral receptor by a
subset of infected cells could have a major con-
tribution to HHV8-induced angiogenesis. This
finding suggests that HHV8 GPCR is a critical
viral gene involved in the pathogenesis of KS,
and points to the dramatic effect of paracrine
stimulation of angiogenesis mediated by VEGF-
A secretion in KS pathogenesis.
On the other hand, the higher viral load
found in KS patients and in late-nodular lesions
suggests that individuals at risk of KS offer bet-
ter conditions to virus growth and spread in the
body. The same cytokine found increased in KS
lesions can maintain and rescue viral growth,
activate viral lytic replication and increase viral
load in B cells and monocytes–macrophages
[200], likely promoting HHV8 transmission to
other cell types.
All factors described above including HHV-8
are present in all forms of KS. However, AIDS-
KS is more frequent and has a more aggressive
F. Bussolino et al. / The International Journal of Biochemistry & Cell Biology 33 (2001) 371–390 381
course than the other KS forms, including AKS
that acquires the most aggressive course after
HIV-1 infection. Again, AIDS patients have at
least 300-fold higher probability to get KS than
individuals with primary immunodeficiency. This
suggests that HIV-I itself may play a role in KS
development.
The earliest evidences to support the role of Tat
in AIDS-KS come from Tat transgenic mice that
develop KS-like lesions [201,202]. Although Tat
expression in both male and female mice was
comparable, lesions developed only in male mice,
mimicking the male predominance. More recently,
another study supports the idea that this molecule
accounts for the aggressiveness of KS in AIDS. In
these animals the growth of KS cells was six fold
higher than that in the non-transgenic mice [203].
In vitro studies indicate the specific role of this
viral protein in activation of KS cells. Tat is
capable of inducing the growth, migration, adhe-
sion and invasion of KS cells [72–74]. KS cells
express both VEGFR2 [88,90,91,136] and 51
and v3 integrins [78,79,82] that are the recep-
tors for Tat mediating EC activation. Further-
more it promotes the synthesis by mesenchymal
cells [204] of basic FGF and has synergistic activ-
ities with this growth factor in activation of KS
cells [74].
Tat has also been shown to activate the adhe-
sion and transmigration across capillaries of
monocytes–macrophages that characterize KS le-
sions and contribute in production of angiogenic
molecules and KS growth factors (see above)
[64,67,97,109].
Extracellular Tat is detectable in AIDS-KS le-
sions and co-stains with these receptors on spindle
cells and activated vessels, suggesting that the
mechanisms described here are operative in vivo
and that Tat may explain the higher frequency
and aggressiveness of KS in the setting of HIV-1
infection [74].
Furthermore, the presence of detectable extra-
cellular Tat in sera from AIDS patients [205], as
well as the presence of antibodies anti-Tat in
AIDS-KS patients, which recognize different epi-
topes as compared with those in AIDS patients
[206] support the hypothesis of its role as a pro-
gression factor in AIDS-KS.
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